Abstract:Ginger is one of the most commonly used herbal medicines for the treatment of numerous ailments and improvement of body functions. It may be used in combination with prescribed drugs. The coadministration of ginger with therapeutic drugs raises a concern of potential deleterious drug interactions via the modulation of the expression and/or activity of drug-metabolizing enzymes and drug transporters, resulting in unfavorable therapeutic outcomes. This study aimed to determine the molecular interactions between 12 main active ginger components (6-gingerol, 8-gingerol, 10-gingerol, 6-shogaol, 8-shogaol, 10-shogaol, ar-curcumene, β-bisabolene, β-sesquiphelandrene, 6-gingerdione, (−)-zingiberene, and methyl-6-isogingerol) and human cytochrome P450 (CYP) 1A2, 2C9, 2C19, 2D6, and 3A4 and to predict the absorption, distribution, metabolism, excretion, and toxicity (ADMET) of the 12 ginger components using computational approaches and comprehensive literature search. Docking studies showed that ginger components interacted with a panel of amino acids in the active sites of CYP1A2, 2C9, 2C19, 2D6, and 3A4 mainly through hydrogen bond formation, to a lesser extent, via π–π stacking. The pharmacokinetic simulation studies showed that the [I]/[Ki] value for CYP2C9, 2C19, and 3A4 ranged from 0.0002 to 19.6 and the R value ranged from 1.0002 to 20.6 and that ginger might exhibit a high risk of drug interaction via inhibition of the activity of human CYP2C9 and CYP3A4, but a low risk of drug interaction toward CYP2C19-mediated drug metabolism. Furthermore, it has been evaluated that the 12 ginger components possessed a favorable ADMET profiles with regard to the solubility, absorption, permeability across the blood–brain barrier, interactions with CYP2D6, hepatotoxicity, and plasma protein binding. The validation results showed that there was no remarkable effect of ginger on the metabolism of warfarin in humans, whereas concurrent use of ginger and nifedipine exhibited a synergistic effect on platelet aggregation in humans. Moreover, ginger components showed a rapid half-life and no to low toxicity in humans. Taken together, this study shows that ginger components may regulate the activity and expression of various human CYPs, probably resulting in alterations in drug clearance and response. More studies are warranted to identify and confirm potential ginger–drug interactions and explore possible interactions of ginger with human CYPs and other functionally important proteins, to reduce and avoid side effects induced by unfavorable ginger–drug interactions.

Analysis of molecular interactions of 8-gingerol compounds in Ginger (Zingiber officinale) as ACE Inhibitor

[6]-Gingerol: A Novel AT1 Antagonist for the Treatment of Cardiovascular Disease

The Biological Function Prediction of The 10-gingerol Compound of Ginger in Inhibiting Cyclooxygenase-2 Activity

Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies

Design, synthesis and investigating the in vitro and in silico HDAC8 inhibitory activities of derivatives of [6]-shogaol and [6]-gingerol isolated from ginger (Zingiber officinale)

Ginger (Zingiber officinale) phytochemicals-gingerenone-A and shogaol inhibit SaHPPK: molecular docking, molecular dynamics simulations and in vitro approaches

Pharmacological Activities of Zingiber officinale Roscoe: Inhibition of HSA Protein Glycation, Structure Stability and Function Restoration

VIRTUAL SCREENING OF ZANTHOXYLUM ACANTHOPODIUM DC. FRUIT BIOACTIVE COMPOUNDS AS NATURAL ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Network pharmacology, molecular docking, and dynamics analyses to predict the antiviral activity of ginger constituents against coronavirus infection

Network pharmacological evaluation for identifying novel drug-like molecules from ginger (Zingiber officinale Rosc.) against multiple disease targets, a computational biotechnology approach

Health Benefits of Antioxidant Bioactive Compounds in Ginger (Zingiber officinale) Leaves by Network Pharmacology Analysis Combined with Experimental Validation

BIOCOMPUTATIONAL AND PHARMACOLOGICAL ANALYSIS OF PHYTOCHEMICALS FROM ZINGIBER OFFICINALE (GINGER), ALLIUM SATIVUM (GARLIC), AND MURRAYAKOENIGII (CURRY LEAF) IN CONTRAST TO TYPE 2-DIABETES

Synthesis of Analogues of Gingerol and Shogaol, the Active Pungent Principles from the Rhizomes of Zingiber officinale and Evaluation of Their Anti-Platelet Aggregation Effects

Optimization of the Extraction Process of Bioactive Compounds from Zingiber officinale Roscoe, Evaluation of Acetylcholinesterase Enzyme Inhibition and Cytotoxic Activity of the Free and Encapsulated Extract

Zingiber officinale: Anti-Oxidant, Anti-Microbial, Anti-Diabetic and Anti-Inflammatory Agent

Cytotoxic and Apoptotic Activities of Diarylheptanoids and Gingerol-Related Compounds from the Rhizome of Chinese Ginger

Preparation and Evaluation of 6-Gingerol Derivatives as Novel Antioxidants and Antiplatelet Agents

Identification of putative α-glucosidase inhibitors and antioxidants in Zingiber officinale rhizome using LCMS-based metabolomics and in silico molecular docking

In silico elucidation for the identification of potential phytochemical against ACE-II inhibitors

Inhibition of Pro-Inflammatory Molecules by Ginger (Zingiber officinale Roscoe) and its Anti-Inflammatory Effects on Arthritis Patients

Bioactive Compounds from the Zingiberaceae Family with Known Antioxidant Activities for Possible Therapeutic Uses